Cytokinetics (NASDAQ:CYTK) quickly rose 7.5% amid some renewed takeover speculation.
There's some speculation that the company has had some fresh bid interest, according to traders, who cited a Betaville "uncooked" alert circulating on Friday.
Cytokinetics (NASDAQ:CYTK) was the subject of takeover speculation last year as several large pharma cos were rumored to be looking at the company.
On Thursday, Morgan Stanley upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target, adding that the stock's risk/reward has skewed to the upside.
Cytokinetics (CYTK) is scheduled to report Q4 results on Feb. 27.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.